Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Figure 2

Disease-free survival (DFS) at 5 years in imatinib and non-imatinib groups, post-HCT. Kaplan-Meier analysis showed that the 5-year DFS of patients in the imatinib-group was significantly higher than in the non-imatinib group (81.5% vs 33.5%, p = 0.000).

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us